AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04108039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Description: Micronized progesterone protocol to avoid LH surge in COS, from stimulation day 1 and continuing until ovulation triggering.
Study NCT01187589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsehaler
Study NCT01187589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulizer & Albuterol 0.5ml
Description: Albuterol aerosolized by a nebulizer
Study NCT01187589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulizer & Albuterol 0.5ml
Description: Albuterol aerosolized by a nebulizer
Study NCT00079352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00079352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00079352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT02766491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening and stretching
Description: Strengthening exercises will be performed 4 times a week for 10 weeks. Single leg heel raises will be the preferred exercise performed. The group of participants will have a wide range of strength and functional abilities, this will be accounted for with individualised programmes. The exercise load can be reduced by switching to bilateral heel raises, giving external support, reducing the range of motion or performing the heel raises while seated. Exercise load will be progressively increased by adding weight in the form of water bottles to a rucksack worn on the participant's back.~For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed.
Study NCT02766491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional stretching
Description: This group will perform seated biceps curls 4 times a week for 10 weeks, where extra load can be added progressively by holding water bottles in the hand.~For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed.
Study NCT04442516 — intervention group
Intervention type: OTHER
Intervention: Questionnaire, sampling of blood, urine and saliva
Description: We are following patients who are receiving Cisplatin as part of their cancer therapy.
Study NCT02256046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscope
Description: Endoscopic therapies for varices aim to reduce variceal wall tension by obliteration of the varix. The two principal methods available for esophageal varices are endoscopic sclerotherapy (EST) and band ligation (EBL). Endoscopic therapy is a local treatment that has no effect on the pathophysiological mechanisms that lead to portal hypertension and variceal rupture. However, a spontaneous decrease in HVPG occurs in around 30% of patients treated with either EST or EBL to prevent variceal rebleeding.
Study NCT03545126 — intervention group
Intervention type: OTHER
Intervention: 13C6 Leucine
Description: Recruited participants will be given 13C6-labeled leucine through intravenous infusion (4mg/kg/hr for 16hrs)
Study NCT01295606 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Cefazolin
Description: iv cefazolin (50mg/kg, 3 times a day) will be given as a routine prophylaxis treatment
Study NCT03541746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: After hysteroscopic adhesiolysis, 30 patients will undergo once injection of 5ml PRP into the wall then lining the uterine cavity by 5ml platelet rich plasma gel. Finally, Foley balloon catheter will be inserted intrauterine then inflated and cutting its stem and to be left for two weeks.
Study NCT03541746 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine Foley's Catheter
Description: After hysteroscopic adhesiolysis, 30 patients will undergo intrauterine insertion of one inflated Foley balloon catheter with cutting its stem only to be left for two weeks.
Study NCT03154710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOOVCARE
Description: web-mediated follow up
Study NCT04688554 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioral questionnaires
Description: RAND 36-item Quality of Life survey, Mini Mental Status Exam, MOCA Cognitive Exam
Study NCT04634227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate
Description: Following 15g test dose, 75g administered 75g dose on days 1 and 2. Further doses of ascorbate will be determined by serum ascorbate levels measured by the end of the week to reach a target serum concentration between 20 -30 mM. Ascorbate doses will continue to be escalated until either the target serum concentration or maximum dose of 125 g is administered.
Study NCT04688554 — intervention group
Intervention type: BEHAVIORAL
Intervention: Disease-Specific Patient-Reported Outcomes
Description: Y-BOCS Survey, QUEST, PDQ39, PHQ2 Depression Screening, PHQ9 Depression Inventory, Beck's Depression Inventory, PROMIS Pain Intensity Short Form 3, McGill Pain Scale, Visual Analog pain scale, FTM (Tremor Scale)
Study NCT04065347 — intervention group
Intervention type: DEVICE
Intervention: Digital Pill
Description: Digital Pill over encapsulating tenofovir alafenamide ART
Study NCT02373124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infusion of NMDA antagonist
Description: 52 minute infusion
Study NCT04527068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/kg intravenously every 3week
Study NCT04527068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripleitriumab
Description: 240mg intravenously every 3week
Study NCT03640663 — intervention group
Intervention type: OTHER
Intervention: Midwife led continuity model of care
Description: Midwives from the hospitals provided outreaching caseload ante- and postnatal care to women in rural villages clinics and homes
Study NCT04179578 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Crura plastic
Description: Closure of hiatus with a running suture
Study NCT03394404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG-I mapping and PVI
Description: ECG-I mapping and PVI
Study NCT04176770 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP Block
Description: ESP block: bilateral injection of 20 ml of isobaric Bupivacain 0,375% in the paraverebral space T5.
Study NCT04176770 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP Block
Description: TAP block: bilateral injection of 15 ml of Isobaric Bupivacain 0,5%
Study NCT04406272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB11
Description: Intravenously administered type of gene therapy that works by blocking the process of blood-vessel creation. Disrupting a cancer from growing blood vessels, might slow the growth of the cancer or shrink it.
Study NCT04406272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.
Study NCT04406272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous solution that has no therapeutic effect, used as a control in testing investigational drug.
Study NCT04406272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: A type of antibody, Bevacizumab is intravenously administered and works by binding to and disrupting the vascular endothelial growth factor (VEGF). VEGF is a signal protein produced by cells that stimulates the formation of blood vessels. By disrupting VEGF, Bevacizumab helps to prevent the growth and maintenance of tumor blood vessels.
Study NCT03197506 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy
Study NCT03197506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03197506 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT01275183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir and cisplatin
Description: Cisplatin, intravenous, 30 mg/m2, days 2 and 16, 1 to 2 hours~Raltegravir, oral,400 mg, twice per day, days 1 through 5 or days 15 to 19~Part 2 (optional): Docetaxel, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles~Part 2 (optional): Cisplatin, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles~Part 2: (optional): Raltegavir, oral, 400 mg, twice per day, days 1 through 5, 3 to 6 cycles
Study NCT03852329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral skull base navigation
Description: Patient preparation: The participant is prepared for the surgery according to clinical standards.~System setup: The hardware components of the investigational device are set up~Tripod fixation: The tripod with integrated registration fiducials is fixed on the participant's skull.~CBCT imaging: A CBCT image of the participant is acquired~Image processing: The CBCT data is loaded on the navigation platform. The registration fiducials are automatically detected in the image data and relevant anatomy is segmented using an otologic planning software.~Measurements: The navigation software is started, and the fiducial positions and segmentations loaded. The measurements are conducted.~Treatment: The surgery is conducted by the surgeon according to clinical standards
Study NCT01728155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Study NCT01728155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Study NCT00368940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATH
Description: PATH utilizes a problem solving approach based on Problem Solving Therapy (PST) and identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies and environmental adaptations that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment. PATH also incorporates caregiver involvement to help patient reduce depression and improve functioning.
Study NCT00368940 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ST-CI
Description: Supportive therapy focuses on the use of nonspecific or common factors of therapy, including facilitation of affect, helping the person feel understood, empathy, the treatment ritual, success experiences, and therapeutic optimism. In working with the participant, the therapist creates a supportive relationship and encourages the participant to consider his/her strengths and abilities rather than focusing on negative aspects of his/her character.
Study NCT02699905 — intervention group
Intervention type: OTHER
Intervention: phlebotomy
Description: phlebotomy
Study NCT01786408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAP20-C
Study NCT01786408 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SAFE-T-FILL CAPILLARY BLOOD COLLECTION SYSTEM
Study NCT01336738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets (n=6), 0 mg, once daily for 84 days
Study NCT01336738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg PF-04991532
Description: Tablets (n=1), 150 mg + tablets (n=5), 0 mg, all once daily for 84 days
Study NCT01336738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 450 mg PF-04991532
Description: Tablets (n=3), 150 mg + tablets (n=3), 0 mg, all once daily for 84 days
Study NCT01336738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 750 mg PF-04991532
Description: Tablets (n=5), 150 mg + tablets (n=1), 0 mg, all once daily for 84 days
Study NCT01336738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100 mg
Description: Tablets (n=1), 100 mg strength + tablets (n=5), 0 mg, all once daily for 84 days
Study NCT03042312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Lutetium (177Lu) -DOTA (1,4,7,10-tetra-azacyclododecane-N,N',N'',N'''-tetraacetic acid )-PSMA has three components: PSMA is the targeting vector , DOTA (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid) is a radiometal chelator and a linking group, and 177Lu is the beta emitter that upon internalization delivers radiation to the nucleus of tumor cells to cause DNA damage. The targeting vector utilizes glu-urea-lys sequence which is an inhibitor capable of binding to the domain of PSMA. These components have been previously used in human subjects and in medical research.
Study NCT01831635 — intervention group
Intervention type: OTHER
Intervention: Methodological pens
Description: Randomisation of branded pen, non-branded pen and no pen
Study NCT01831635 — intervention group
Intervention type: OTHER
Intervention: Methodological compensation
Description: Randomisation of a £10 monetary reimbursement for expenses on completion of the study
Study NCT01831635 — intervention group
Intervention type: OTHER
Intervention: Methodological trolley tokens
Description: Trolley tokens to be randomly assigned to half of cases and General Practice controls.
Study NCT00543881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring (Partnership for the Heart)
Description: Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits plus daily monitoring of ECG, weight, blood pressure, self-report of health status, weekly monitoring of physical fitness
Study NCT00543881 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care group
Description: Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits
Study NCT03162250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSTA4637S
Description: DSTA4637S will be administered as an IV infusion at 3 dose levels.
Study NCT03162250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to DSTA4637S IV infusion will be administered as specified.
Study NCT03162250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: Anti-staphylococcal SOC antibiotics dosage and duration of therapy will be based on relevant health-authority approved indications and local and national treatment guidelines.
Study NCT03197506 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT03197506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT02023034 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Virtual exercises
Description: The exercises will be performed with the Nintendo ® Wii Balance Board ® platform, and consist in: 1) Table Tilt; 2) Obstacle Course; 3) Tilt City; 4) Basic step; 5) Penguin; 6) Heading Soccer; 7) Basic Run. All patients underwent 12 sessions, twice a week for a period of 06 weeks.
Study NCT02023034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual exercises
Description: The exercises will be performed with the Nintendo ® Wii Balance Board ® platform, and consist in: 1) Table Tilt; 2) Obstacle Course; 3) Tilt City; 4) Basic step; 5) Penguin; 6) Heading Soccer; 7) Basic Run. All patients underwent 12 sessions, twice a week for a period of 06 weeks.
Study NCT04499404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding related information delivered by WeChat
Description: Participants in the intervention group will be asked to follow our WeChat public account immoderately after randomization. They will receive breastfeeding related messages three times a week from WeChat, including preparation for breastfeeding after birth and the health benefits of breastfeeding, from baseline until childbirth. After childbirth, intervention group mothers will continue to receive information, which is mainly about breastfeeding, once a week for 6 months. WeChat will send push notifications to remind mothers about the importance of exclusive breastfeeding, build confidence and motivate them to continue exclusive breastfeeding.
Study NCT04499404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-breastfeeding related information delivered by WeChat
Description: Participants in the control group will be asked to follow our WeChat public account immoderately after randomization. They will receive messages mainly on topics of healthy lifestyle and nutrition during pregnancy, from baseline until childbirth. After childbirth, they will continue to receive information on other topics of interest to mothers, such as immunization, safety, infant growth, and etc., until 6 months postpartum.
Study NCT03197506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT04192747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous coronary intervention of de novo native coronary artery lesions
Study NCT04192747 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous coronary intervention of de novo native coronary artery lesions
Study NCT04190745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab+Apatinib mesylate
Description: Toripalimab 240mg, ivgtt, Q3w Apatinib mesylate 250mg PO. QD
Study NCT04190745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 80mg/m2, q3w
Study NCT02359266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Given to patients with existing vitamin D deficiency
Study NCT00585065 — intervention group
Intervention type: DEVICE
Intervention: CRT device implant
Description: The purpose of this study is to collect information on patients with chronic heart failure who have already been identified by their physician as candidates for CRT. All tests, including device implantation are standard of care for patients undergoing CRT. The only test involved in this study that is not standard of care is the quality of life questionnaire. Patients who undergo CRT system implant will be followed post-implant (up to 1 week), and at one month, three months, six months and twelve months. The only test involved in this study that is not standard of care is the quality of life questionnaire.
Study NCT02352324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid responsiveness tests
Description: After the end of surgery in ICU the positive end-expiratory pressure (PEEP) test of 15 cm H2O for 300 seconds will be performed. Following PEEP test, the two-step fluid load test of 6 ml/kg balanced crystalloid solution will be performed sharing in two portions: Initial mini FLT (mFLT) of 1.5 ml/kg within 1 min (approximately 100 mL) followed by the registration of continuous CI and traditional fluid responsiveness parameters and the rest of standard FLT (4.5 mL/kg) within 5 minutes (approximately 350 mL) followed by transpulmonary thermodilution, registration of continuous cardiac index (CI) and classic fluid responsiveness parameters.
Study NCT03873285 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic diagnostic by mendeliome or genome
Description: For cases not explained by a mendeliomes: genome and transcriptome on fibroblast culture
Study NCT02659865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT02659865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478 original formulation
Description: Administered orally
Study NCT02659865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478 new formulation
Description: Administered orally
Study NCT03919175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Umbralisib is an investigational drug which blocks a protein called PI3K. PI3K is a protein that plays a role in the way cells grow. In this type of cancer, PI3K is increased and more active than usual. This helps the cancer cells to grow and survive.
Study NCT03919175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
Study NCT00672477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Study NCT00672477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03986944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg linzagolix tablet
Description: For oral administration once daily
Study NCT03986944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg linzagolix tablet
Description: For oral administration once daily
Study NCT03986944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add-back capsule (E2 1 mg / NETA 0.5 mg)
Description: For oral administration once daily
Study NCT03986944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet to match 75 mg linzagolix tablet
Description: For oral administration once daily
Study NCT03986944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet to match 75 mg linzagolix tablet
Description: For oral administration once daily
Study NCT03986944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet to match 200 mg linzagolix tablet
Description: For oral administration once daily
Study NCT03986944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet to match 200 mg linzagolix tablet
Description: For oral administration once daily